These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25134421)

  • 1. Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients.
    Kowalec K; Kingwell E; Yoshida EM; Marrie RA; Kremenchutzky M; Campbell TL; Wadelius M; Carleton B; Tremlett H
    Expert Opin Drug Saf; 2014 Oct; 13(10):1305-17. PubMed ID: 25134421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study.
    Chan S; Kingwell E; Oger J; Yoshida E; Tremlett H
    Mult Scler; 2011 Mar; 17(3):361-7. PubMed ID: 21148660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the safety of β-interferons in MS: A series of nested case-control studies.
    de Jong HJI; Kingwell E; Shirani A; Cohen Tervaert JW; Hupperts R; Zhao Y; Zhu F; Evans C; van der Kop ML; Traboulsee A; Gustafson P; Petkau J; Marrie RA; Tremlett H;
    Neurology; 2017 Jun; 88(24):2310-2320. PubMed ID: 28500224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.
    Byrnes V; Afdhal N; Challies T; Greenstein PE
    Ann Hepatol; 2006; 5(1):56-9. PubMed ID: 16531969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature.
    Salk A; Stobaugh DJ; Deepak P; Ehrenpreis ED
    Ann Pharmacother; 2013 Apr; 47(4):537-42. PubMed ID: 23535814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver injury associated with the beta-interferons for MS: a comparison between the three products.
    Tremlett HL; Yoshida EM; Oger J
    Neurology; 2004 Feb; 62(4):628-31. PubMed ID: 14981183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
    Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
    JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C; Oger J; Gibbs E; Grossberg SE;
    Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presentation and outcomes with clinically apparent interferon beta hepatotoxicity.
    Fontana RJ; Hayashi P; Bonkovsky HL; Kleiner DE; Kochhar S; Gu J; Ghabril M
    Dig Dis Sci; 2013 Jun; 58(6):1766-75. PubMed ID: 23377559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS.
    Stewart N; Simpson S; van der Mei I; Ponsonby AL; Blizzard L; Dwyer T; Pittas F; Eyles D; Ko P; Taylor BV
    Neurology; 2012 Jul; 79(3):254-60. PubMed ID: 22700816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety liver profile of teriflunomide versus interferon β in multiple sclerosis: Systematic review and indirect comparison meta-analysis.
    Salas PAO; Parra CO; Florez CEP; Goez LM; Velez-van-Meerbeke A; Rodriguez JH
    Mult Scler Relat Disord; 2018 Nov; 26():192-200. PubMed ID: 30268040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unmasking autoimmune hepatitis under immunomodulatory treatment of multiple sclerosis--not only beta interferon.
    von Kalckreuth V; Lohse AW; Schramm C
    Am J Gastroenterol; 2008 Aug; 103(8):2147-8; author reply 2148. PubMed ID: 18796115
    [No Abstract]   [Full Text] [Related]  

  • 14. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study.
    Shirani A; Zhao Y; Karim ME; Petkau J; Gustafson P; Evans C; Kingwell E; van der Kop ML; Oger J; Tremlett H
    Eur J Neurol; 2014 Jun; 21(6):835-44. PubMed ID: 24351059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs.
    Lu E; Zhu F; Zhao Y; van der Kop M; Synnes A; Dahlgren L; Sadovnick AD; Traboulsee A; Tremlett H
    CNS Drugs; 2014 May; 28(5):475-82. PubMed ID: 24643915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study.
    Evans C; Tam J; Kingwell E; Oger J; ; Tremlett H
    Clin Ther; 2012 Feb; 34(2):341-50. PubMed ID: 22296946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Interferon beta treatment on quality of life in multiple sclerosis patients.
    Simone IL; Ceccarelli A; Tortorella C; Bellacosa A; Pellegrini F; Plasmati I; De Caro MF; Lopez M; Girolamo F; Livrea P
    Health Qual Life Outcomes; 2006 Dec; 4():96. PubMed ID: 17163989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of drug-induced liver injury from tumor necrosis factor antagonists.
    Björnsson ES; Gunnarsson BI; Gröndal G; Jonasson JG; Einarsdottir R; Ludviksson BR; Gudbjörnsson B; Olafsson S
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):602-8. PubMed ID: 25131534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective.
    Tremlett HL; Oger J
    Mult Scler; 2008 Jan; 14(1):94-105. PubMed ID: 17881392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.